Research
Researchers at the German Center for Infection Research (DZIF) at Heidelberg Faculty of Medicine have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team led by DZIF scientist Dr. Marina Lusic identified RNA:DNA hybrids (R-loops) as molecular signposts for the virus. These findings reveal a key […]
read more
Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay
Researchers from Heidelberg University’s Medical Faculty, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases (NCT) in Heidelberg have tested the use of targeted drugs in the initial treatment of newly diagnosed glioblastoma, an extremely aggressive brain tumor, in the multicenter study “NCT Neuro Master Match (N2M2)”. Of the five drugs […]
read more
Global effort to sequence all life on Earth ramps up
The Earth BioGenome Project is accelerating its efforts tenfold to sequence all life on Earth by 2035 Summary A global collaboration that includes experts at EMBL’s European Bioinformatics Institute (EMBL-EBI) has entered the second phase of its ambitious plan to sequence all 1.67 million known species on Earth by 2035. The Earth BioGenome Project (EBP), a […]
read more
After EMBL: Umlaut.bio and its potential role in drug development
Alumnus Bastian Linder discusses the origin of this start-up and how a tRNA mechanism is helping scientists understand the importance and use of various RNA modifications as they pertain to disease. With just two dots above a letter, the German umlaut can instantly change a word’s pronunciation, its quantity (singular to plural), or even its […]
read more
Rare bone tumors: Tailor-made mini-proteins switch off tumor drivers
Chordomas are rare bone tumors for which there are currently no effective drugs. A research team from the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) Heidelberg has now developed a promising approach: Tailor-made mini-proteins specifically block the central driver of tumor development. In the result, they slowed the growth […]
read more
Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference
Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors. In a mouse […]
read more
Key Mechanism for Alzheimer’s Disease Discovered
Researchers identify neurotoxic protein complex – Pharmacological inhibitor opens up new perspectives for the development of effective therapies A molecular mechanism that significantly contributes to the progression of Alzheimer’s disease has been discovered by a research team led by neurobiologist Prof. Dr Hilmar Bading of Heidelberg University. In joint experiments with researchers from Shandong University […]
read more
Inhibition of cell division induces immunoreactive peptides in cancer cells
A team of scientists from the German Cancer Research Center (DKFZ) and the Netherlands Cancer Institute has discovered a previously unknown vulnerability in cancer cells: When cell division is blocked with chemotherapeutic agents such as Taxol, cancer cells produce small immunogenic peptides that could open up new avenues for immune-based cancer therapies. Frequent cell division […]
read more
New Headquarters – PL BioScience Announces Major Site Expansion in September 2025
Key Milestone for PL BioScience as new headquarters are announced PL BioScience announced the next major step in its expansion – an upcoming move to a new 1,200 m² facility in Aachen, in September 2025. This key milestone will support the company’s growth and upscaling efforts, and provide the world’s largest HPL output, with 20,000L […]
read more
